Neuroscience

MIRA Pharmaceuticals Announces Ketamir-2 Outperforms Current FDA-Approved Neuropathic Pain Treatments, Gabapentin and Pregabalin, in Preclinical StudyMIRA Pharmaceuticals Announces Ketamir-2 Outperforms Current FDA-Approved Neuropathic Pain Treatments, Gabapentin and Pregabalin, in Preclinical Study

MIRA Pharmaceuticals Announces Ketamir-2 Outperforms Current FDA-Approved Neuropathic Pain Treatments, Gabapentin and Pregabalin, in Preclinical Study

MIAMI, FL / ACCESSWIRE / October 21, 2024 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA), a leading pre-clinical-stage pharmaceutical development company, is…

8 months ago
Supernus Announces Promising Data from Open-Label Phase 2a Study of SPN-820 in Adults with Major Depressive DisorderSupernus Announces Promising Data from Open-Label Phase 2a Study of SPN-820 in Adults with Major Depressive Disorder

Supernus Announces Promising Data from Open-Label Phase 2a Study of SPN-820 in Adults with Major Depressive Disorder

Phase 2a study demonstrated rapid and substantial decrease in depressive symptoms SPN-820 was well-tolerated with few adverse events SPN-820 is…

8 months ago
Nikon Small World Competition Celebrates 50 Years with Groundbreaking Image of Brain Tumor CellsNikon Small World Competition Celebrates 50 Years with Groundbreaking Image of Brain Tumor Cells

Nikon Small World Competition Celebrates 50 Years with Groundbreaking Image of Brain Tumor Cells

Celebrating its golden anniversary, Nikon Small World honors a stunning photo of brain tumor cell structures, advancing our understanding of…

8 months ago
Linus Health Leader to Join ‘Brainiacs’ Panel at HLTH 2024 to Discuss Advancements in Cognitive Impairment ScreeningLinus Health Leader to Join ‘Brainiacs’ Panel at HLTH 2024 to Discuss Advancements in Cognitive Impairment Screening

Linus Health Leader to Join ‘Brainiacs’ Panel at HLTH 2024 to Discuss Advancements in Cognitive Impairment Screening

Company also a finalist for Digital Health Awards to be announced on opening night BOSTON, Oct. 17, 2024 /PRNewswire/ --…

8 months ago
Sarah Sheikh Joins Cerevance’s Board of DirectorsSarah Sheikh Joins Cerevance’s Board of Directors

Sarah Sheikh Joins Cerevance’s Board of Directors

BOSTON, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Cerevance, a clinical-stage biopharmaceutical company advancing multiple cell type-specific therapies for the treatment…

8 months ago
Noema Pharma Announces NOE-105 (gemlapodect) Phase 2a Study in Tourette Syndrome met Primary and all Key Secondary EndpointsNoema Pharma Announces NOE-105 (gemlapodect) Phase 2a Study in Tourette Syndrome met Primary and all Key Secondary Endpoints

Noema Pharma Announces NOE-105 (gemlapodect) Phase 2a Study in Tourette Syndrome met Primary and all Key Secondary Endpoints

– Topline results from Phase 2a study – Nearly 60% of all patients treated with gemlapodect and 88% of patients…

8 months ago
Monument Therapeutics Secures £1M Investment to Fund Its Schizophrenia Programme And Drive Next Stage of GrowthMonument Therapeutics Secures £1M Investment to Fund Its Schizophrenia Programme And Drive Next Stage of Growth

Monument Therapeutics Secures £1M Investment to Fund Its Schizophrenia Programme And Drive Next Stage of Growth

MANCHESTER, England, Oct. 15, 2024 /PRNewswire/ -- Monument Therapeutics, a precision neuroscience company, today announced a further £1M equity investment…

8 months ago
Neurophet-AriBio to develop ‘Next-Gen Platform for Alzheimer’s diagnosis’Neurophet-AriBio to develop ‘Next-Gen Platform for Alzheimer’s diagnosis’

Neurophet-AriBio to develop ‘Next-Gen Platform for Alzheimer’s diagnosis’

- Neurophet's brain MRI analysis technology incorporates fluid biomarker data from AriBio's global Phase 3 clinical trial for Alzheimer's disease…

8 months ago
Perceiv AI Welcomes Simona Skerjanec to Board of DirectorsPerceiv AI Welcomes Simona Skerjanec to Board of Directors

Perceiv AI Welcomes Simona Skerjanec to Board of Directors

Thought Leader in Brain Health Joins Richard Stark and Company Co-Founders to Accelerate Innovation in Precision MedicineMONTREAL, QC / ACCESSWIRE…

8 months ago
Awakn Partners with the University of Nottingham for in Vivo Testing of Aminoindane New Chemical Entity (NCE) Pre-Clinical ProgramAwakn Partners with the University of Nottingham for in Vivo Testing of Aminoindane New Chemical Entity (NCE) Pre-Clinical Program

Awakn Partners with the University of Nottingham for in Vivo Testing of Aminoindane New Chemical Entity (NCE) Pre-Clinical Program

Toronto, Ontario--(Newsfile Corp. - October 15, 2024) - Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn" or…

8 months ago